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ORIGINAL ARTICLE MYCOLOGYInitial serum (1,3)-β-D-glucan as a predictor of mortality in proven
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in Italy and BrazilD. R. Giacobbe1, P. Esteves2, P. Bruzzi3, M. Mikulska1, E. Furfaro1, A. Mesini1, P. Tatarelli1, S. Grignolo1, C. Viscoli1,
A. L. Colombo2 and V. Del Bono1
1) Clinica Malattie Infettive, DIPMI, DISSAL, IRCCS San Martino-IST, Università di Genova, Genoa, Italy, 2) Escola Paulista de Medicina, Universidade Federal de
São Paulo, São Paulo, Brazil and 3) U.O. Epidemiologia clinica e studi controllati, IRCCS San Martino-IST, San Martino, ItalyAbstractA retrospective study was conducted to assess the role of initial serum (1,3)-β-D-glucan (BDG) values in predicting mortality in proven
candidaemia. The study was conducted in two large teaching hospitals in Italy and Brazil. From January 2009 to June 2014, all patients
with proven candidaemia who underwent a BDG test within 96 hours before or after the ﬁrst positive blood culture were included in
the study. The primary end point was 28-day mortality, with the role of initial BDG being assessed by univariate and multivariate
analyses. A total of 104 patients met the inclusion criteria. Overall, the crude 28-day mortality was 30% (31/104). In the ﬁnal multivariate
model, an initial BDG of >287 pg/mL (odds ratio (OR) 4.40, 95% conﬁdence interval (CI) 1.56–12.39, p 0.005), haemodialysis (OR 4.33,
95% CI 1.24–15.17, p 0.022) and a Pitt score of 2 (OR 4.10, 95% CI 1.24–13.54, p 0.021) were signiﬁcant predictors of 28-day
mortality. The >287 pg/mL cutoff predicted 28-day mortality with 65% sensitivity and 70% speciﬁcity. Centre of enrolment (p for
interaction 0.012), haemodialysis (p for interaction 0.062) and timing of BDG test of more than 24 hours before or after the positive
culture (p for interaction 0.143) appeared to interact with BDG’s ability to predict mortality. Although not statistically signiﬁcant, the last
two of these interactions might partially explain why BDG’s ability to predict mortality was present only in the Italian cohort.
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E-mail: daniele.roberto.giacobbe@gmail.comIntroductionBloodstream infections due to Candida spp. are serious clinical
events as a result of the high mortality associated with these
infections [1,2].
A positive blood culture for Candida spp. is the mainstay of
the diagnosis of candidaemia, although the sensitivity of bloodMicrobiol Infect 2015; 21: 954.e9–954.e17
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.06.002cultures may be as low as 50% [3,4]. In addition, cultures may
take several days to grow, particularly for certain species of
Candida, such as C. glabrata, resulting in delayed diagnosis and
treatment administration [5]. Against this backdrop, serologic
markers of candidaemia like serum (1,3)-β-D-glucan (BDG), a
fungal cell wall component of Candida spp. and other pathogenic
fungi, were developed as useful tools for early diagnosis and
treatment [6–10].
Besides its use as a diagnostic tool, BDG has also been
investigated as a predictor of clinical response. An initial BDG
value of <416 pg/mL predicted treatment success in subjects
with candidaemia and other forms of invasive candidiasis
enrolled onto a clinical trial and treated with anidulafungin [11].
In addition, several studies have shown a correlation between aious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Giacobbe et al. Serum (1,3)-β-D-glucan as predictor of mortality 954.e10decrease in BDG levels and response to antifungal therapy in
case of invasive fungal diseases [12–14]. However, the possible
impact of the initial BDG value on mortality has not been
studied. With this aim, a retrospective study was conducted in
two large teaching hospitals in Italy and Brazil to assess pre-
dictors of mortality in subjects with proven candidaemia,
focusing in particular on the role of initial BDG levels.Materials and MethodsStudy design and settings
This retrospective study was performed in IRCCS AOU San
Martino– IST University Hospital, Genoa, Italy (institution 1),
and in UNIFESP University Hospital, São Paulo, Brazil (institu-
tion 2). The two hospitals have the following characteristics:
institution 1, 1300 beds; 473 000 patient-days per year; 5 adult
medical and surgical intensive care units; and institution 2, 750
beds; 177 000 patient-days per year; nine adult and paediatric,
medical and surgical intensive care units. From January 2009 to
June 2014, all adult patients (18 years or older) with proven
candidaemia who underwent BDG testing within 96 hours
before or after the ﬁrst positive blood culture were identiﬁed
through clinical and laboratory databases. Proven candidaemia
was deﬁned as recovery of Candida spp. from blood in the
presence of signs and symptoms of infection, according to the
deﬁnition of the European Organization for Research and
Treatment of Cancer/National Institute of Allergy and Infec-
tious Diseases Mycoses Study Group [15]. Patients with
probable or proven invasive fungal diseases due to fungi other
than Candida spp. were excluded from the study [15]. Patients
were included in the study only once, at the time of the ﬁrst
positive blood culture. Medical charts and laboratory databases
were reviewed to collect all available clinical and microbiologic
data. All surviving patients were followed for at least 28 days.
Data collected for analysis
The following variables were evaluated as predictors of mor-
tality: age; gender; centre (Italy vs. Brazil); previous hospitali-
zations (within 6 months); previous surgical procedures (within
30 days); previous chemotherapy (within 30 days); previous
transplantation (haematopoietic stem cell transplantation or
solid organ transplantation); presence of a solid neoplasm;
presence of a haematologic malignancy; receipt of corticoste-
roid therapy; receipt of immunosuppressive drugs; diabetes
mellitus; Charlson comorbidity index score [16]; previous
candidaemia (within 30 days); type of specialty ward (surgery,
medicine or intensive care unit) where candidaemia developed;
species of Candida; other sites of fungal infection aside from
blood; presence of a central venous catheter (CVC);Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infneutropenia at time of infection (deﬁned as absolute neutrophil
count of <500/mm3); serum creatinine values at time of infec-
tion; haemodialysis; Pitt bacteraemia score [17]; time from
hospital admission to candidaemia; time from candidaemia to
antifungal therapy; type of antifungal therapy; presence of a
concomitant bacteraemia; concomitant administration of iv
antibacterial therapy; initial serum BDG levels; and timing of
BDG test with respect to time of the positive blood culture (24
hours or less vs. more than 24 hours).
Detection of BDG and microbiologic methodology
BDG evaluation was performed with the Fungitell assay (As-
sociates of Cape Cod, Cape Cod, MA, USA). All samples were
stored at −20°C, and assays were performed according to the
manufacturer’s recommendations. Identiﬁcation of Candida spp.
was performed by the VITEK 2 automated system (bioMérieux,
Marcy l’Etoile, France).
Statistical analysis
The primary study analysis was the identiﬁcation of risk factors
associated with 28-day mortality. To this aim, the aforemen-
tioned potential predictors of mortality were compared be-
tween patients who survived through the 28th day and patients
who died within 28 days by means of the chi-square test, the 2-
tailed Fisher exact test or the Mann-Whitney U test, as
appropriate. As shown in Fig. 1, the distribution of the initial
BDG was bimodal, thus supporting its dichotomization. The
cutoff value was chosen arbitrarily before analyses (in order not
to be inﬂuenced by patient outcome) as the midpoint of the
largest zero interval of the distribution of initial BDG values in
all patients. To assess the independent role of variables, a
multivariate logistic model was ﬁtted to the data, considering all
variables that had shown an association (p <0.15) with mortality
in the univariate analysis. The ﬁnal model was built by means of
a stepdown procedure based on the likelihood ratio test. Odds
ratios (OR; computed by exponentiating the multiple regres-
sion coefﬁcients) with their 95% conﬁdence intervals (CI) are
presented.
Sensitivity, speciﬁcity, positive predictive value (PPV) and
negative predictive value (NPV) of various initial BDG cutoffs,
including that chosen before analyses, were computed with
standard methods. For an overall assessment of the discrimi-
nant power of the test, a receiver operating characteristic
(ROC) curve was plotted.
The modifying effect of all signiﬁcant predictors of mortality
retained in the ﬁnal multivariate model on the predictive ability
of the BDG test was evaluated by means of standard subgroup
analysis techniques—that is, by adding to the multivariate lo-
gistic regression model the appropriate terms for interactions
and evaluating their contribution to the likelihood of the model.ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 954.e9–954.e17
FIG. 1. Distribution of initial BDG levels. Values of >500 pg/mL also include all initial BDG values of >523 pg/mL. Because maximum detectable BDG
level in Fungitell assay is set at 523 pg/mL, true levels above this cutoff could not be measured. In 23 cases (22%) BDG test was performed before
positive blood culture, while in 81 cases (78%) it was performed after positive blood culture. True frequencies are as follows: −96 to −72 hours
(n = 3), −72 to −48 hours (n = 0), −48 to 24 hours (n = 2), −24 to 0 hours (n = 18), 0 to +24 hours (n = 25), +24 to +48 hours (n = 28), +48 to +72
hours (n = 14) and +72 to + 96 hours (n = 14). BDG, (1,3)-β-D-glucan; ±24 h, 24 hours before or after the positive blood culture.
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TABLE 1. Baseline characteristics of patients according to
enrolment centrea
Variableb
Brazilian
cohort
Italian
cohort OR (95% CI) p
Patient demographics
Patients 35 (34) 69 (66) —
Age (years) 56 (49–65) 70 (57–79) — < 0.001
Male gender 23 (66) 43 (62) 1.16 (0.50–2.71) 0.831
Medical history
Previous
hospitalization
15 (43) 30 (44) 0.98 (0.43–2.22) 0.952
CMI Giacobbe et al. Serum (1,3)-β-D-glucan as predictor of mortality 954.e12Given the exploratory nature of these analyses, no correction
for multiple testing was used. The possible modifying effect of
the centre of enrolment was also evaluated, along with that of
other variables potentially interfering with serum BDG levels,
such as haemodialysis, timing of BDG test with respect to time
of the positive blood culture, timing of initiation of antifungals
with respect to BDG test and presence of concomitant bac-
teraemia [18].Previous ICU 5 (14) 9 (13) 1.11 (0.34–3.61) 1.000
Previous candidaemia 0 (0) 2 (3) — 0.549
Previous surgical
procedures
20 (57) 26 (38) 2.21 (0.96–5.05) 0.059
Previous 4 (11) 12 (17) 0.61 (0.18–2.06) 0.426
Resultschemotherapy
Previous solid organ
transplant
7 (20) 1 (1) 16.42
(1.92–140.29)
0.002
Previous HSCT 2 (6) 7 (10) 0.67 (0.13–3.45) 0.714
Solid neoplasm 5 (14) 21 (30) 0.38 (0.13–1.19) 0.072
Haematologic
malignancy
4 (11) 13 (19) 0.56 (0.17–1.85) 0.334
Corticosteroid
therapy
7 (21) 22 (39) 0.40 (0.15–1.08) 0.066
Missing 1 13
Immunosuppressive
therapy
7 (21) 3 (5) 4.92 (1.18–20.54) 0.033
Missing 1 9
Diabetes 9 (26) 10 (15) 2.04 (0.74–5.62) 0.162
Charlson comorbidity
index score 2
16 (46) 50 (73) 0.32 (0.14–0.75) 0.007
Infection variables
Time from admission
to candidaemia
(days)
15 (12–24) 20 (6–31) — 0.951
ICU stay at time of
infection
19 (54) 14 (20) 4.67 (1.92–11.33) <0.001
Non-albicans Candida
spp.
19 (54) 36 (52) 1.09 (0.48–2.46) 0.838
Candidaemia due to
more than one
Candida spp.
1 (3) 4 (6) 0.48 (0.05–4.45) 0.661
Other sites of infection
aside from blood
4 (11) 3 (4) 2.84 (0.60–13.46) 0.221
Presence of CVC 30 (86) 56 (81) 1.39 (0.45–4.28) 0.785
Concomitant
bacteraemia
5 (14) 22 (32) 0.36 (0.12–1.04) 0.053
Patient variables
Neutropenia (ANC
<500/mm3)
2 (6) 5 (7) 0.78 (0.14–4.21) 1.000
Serum creatinine
>2-fold ULN
12 (34) 8 (12) 3.98 (1.44–10.98) 0.006
Haemodialysis 12 (34) 4 (6) 8.48 (2.48–28.93) < 0.001
Pitt score 2 24 (71) 36 (57) 1.80 (0.74–4.39) 0.193
Missing 1 6
Timing of BDG
test > ±24 hoursc
32 (91) 29 (42) 14.71 (4.11–52.72) < 0.001
28-day mortality 13 (37) 18 (26) 1.67 (0.70–4.00) 0.244
ANC, absolute neutrophil count; BDG, (1,3)-β-D-glucan; CI, conﬁdence intervals;
CVC, central venous catheter; HSCT, haematopoietic stem cell transplantation;
ICU, intensive care unit; OR, odds ratio; ULN, upper limit of normal (set at 1.3 mg/
dL)
aData are presented as median (interquartile range) or n (%).
bMissing refers to data not available in medical charts or databases.
cWith respect to the positive blood culture for Candida spp.; ±24 h, 24 hours
before or after the positive blood culture.During the study period, we observed 104 episodes of candi-
daemia that met the study inclusion criteria, 35 (34%) and 69
(66%) occurring in Brazil and Italy, respectively.
The overall 28-day mortality was 30% (31/104 subjects).
Table 1 reports the details of baseline patients’ characteristics
and outcome according to centre of enrolment. There was a
considerable difference in the median age of the two pop-
ulations, being 70 years (interquartile range 57–79 years) and
56 years (interquartile range 49–65 years) in the Italian and in
the Brazilian cohorts, respectively. It is of note that the Brazilian
cohort was more likely than the Italian cohort to include
intensive care unit patients (54% vs. 20%), patients receiving
haemodialysis (34% vs. 6%) and patients having an initial BDG
test performed more than ±24 hours from the ﬁrst positive
blood culture (91% vs. 42%).
A BDG cutoff value of 287 pg/mL was chosen on the basis of
the bimodal distribution shown in Fig. 1. Mortality at 28 days
was 18% (11/62 subjects) and 48% (20/42 subjects) in patients
with initial BDG levels of 287 pg/mL and >287 pg/mL,
respectively. To assess whether the difference in mortality was
still signiﬁcant after having adjusted for other risk factors for
mortality, both a univariate and a multivariate analysis were
performed.
Table 2 shows the univariate analysis of factors associated
with 28-day mortality. An initial BDG of >287 pg/mL (OR 4.22,
95% CI 1.73–10.26, p 0.001), a baseline serum creatinine >2-
fold the upper limit of normal (OR 3.00, 95% CI 1.10–8.21, p
0.028), haemodialysis (OR 3.86, 95% CI 1.29–11.58, p 0.018)
and a Pitt bacteraemia score of 2 (OR 4.57, 95% CI
1.56–13.70, p 0.004) were signiﬁcantly associated with
increased mortality. Although not statistically signiﬁcant, an
intriguing association with reduced mortality was observed for
male gender (OR 0.49, 95% CI 0.21–1.15, p 0.102) and pre-
vious surgical procedures (OR 0.49, 95% CI 0.20–1.19, p
0.109). Of note, removal of CVC during candidaemia occurred
more frequently in survivors (47/59, 80%) than in nonsurvivors
(16/27, 59%). However, this comparison was not further
considered in this study because its validity is undermined byClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infthe obvious bias caused by the fact that patients who died had a
shorter period of observation.
The multivariate model retained the following variables as
factors signiﬁcantly and unfavourably associated with 28-day
mortality: an initial BDG value of >287 pg/mL (OR 4.40, 95%
CI 1.56–12.39, p 0.005); haemodialysis (OR 4.33, 95% CI
1.24–15.17, p 0.022); and a Pitt score of 2 (OR 4.10, 95% CI
1.24–13.54, p 0.021). Results of the multivariate analysis are
reported in Table 3; Table 4 reports the sensitivity, speciﬁcity,ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 954.e9–954.e17
TABLE 2. Univariate analysis of risk factors for 28-day
mortality in patients with candidaemiaa
Characteristicb Total Nonsurvivors OR (95% CI) p
Overall 104 31 (30)
Age 0.536
<56 years 35 8 (23) 1 (ref)
56–70 years 35 12 (34) 1.76 (0.61–5.05)
70 years 34 11 (32) 1.61 (0.56–4.69)
Gender 0.102
Female 38 15 (39) 1 (ref)
Male 66 16 (24) 0.49 (0.21–1.15)
Centre
Brazil 35 13 (37) 1 (ref) 0.244
Italy 69 18 (26) 0.60 (0.25–1.43)
Previous
hospitalization
0.286
No 59 15 (25) 1 (ref)
Yes 45 16 (36) 1.62 (0.69–3.77)
Previous ICU 0.547
No 90 28 (31) 1 (ref)
Yes 14 3 (21) 0.60 (0.16–2.34)
Previous candidaemia 0.509
No 102 30 (29) 1 (ref)
Yes 2 1 (50) 2.4 (0.15–36.64)
Previous surgical
procedures
0.109
No 58 21 (36) 1 (ref)
Yes 46 10 (22) 0.49 (0.20–1.19)
Previous
chemotherapy
0.465
No 88 25 (29) 1 (ref)
Yes 16 6 (38) 1.51 (0.50–4.60)
Previous
transplantation
0.169
No 87 23 (26) 1 (ref)
HSCT 9 5 (56) 3.48 (0.86–14.08)
Solid organ 8 3 (38) 1.67 (0.37–7.58)
Solid neoplasm 0.265
No 78 21 (27) 1 (ref)
Yes 26 10 (38) 1.70 (0.67–4.32)
Haematologic
malignancy
0.589
No 87 25 (29) 1 (ref)
Yes 17 6 (35) 1.35 (0.45–4.06)
Corticosteroid
therapy
0.978
No 61 17 (28) 1 (ref)
Yes 29 8 (28) 0.99 (0.37–2.65)
Missing 14
Immunosuppressive
therapy
0.925
No 84 24 (29) 1 (ref)
Yes 10 3 (30) 1.07 (0.26–4.49)
Missing 10
Diabetes 0.713
No 85 26 (31) 1 (ref)
Yes 19 5 (26) 0.81 (0.26–2.49)
Charlson comorbidity
index score 2
0.884
No 38 11 (29) 1 (ref)
Yes 66 20 (30) 1.07 (0.45–2.56)
Time from admission
to candidaemia
(days)
16 (8–29) 14 (5–27) — 0.553
Ward where
candidaemia
developed
0.592
Surgical/medical 71 20 (28) 1 (ref)
ICU 33 11 (33) 1.28 (0.52–3.10)
Species of Candida 0.866
C. albicans 49 15 (31) 1 (ref)
Non-albicans
Candida spp.c
55 16 (29) 0.93 (0.40–2.16)
Candidaemia due to >1
Candida spp.d
0.633
No 99 29 (29) 1 (ref)
Yes 5 2 (40) 1.61 (0.26–10.14)
Other sites of infection
aside from blood
1.000
No 97 29 (30) 1 (ref)
Yese 7 2 (29) 0.94 (0.17–5.12)
Presence of CVC 0.439
No 18 4 (22) 1 (ref)
Yes 86 27 (31) 1.60 (0.48–5.32)
Neutropenia (ANC
<500/mm3)
1.000
No 97 29 (30) 1 (ref)
TABLE 2. Continued
Characteristicb Total Nonsurvivors OR (95% CI) p
Yes 7 2 (29) 0.94 (0.17–5.11)
Serum creatinine >2-
fold ULN
0.028
No 84 21 (25) 1 (ref)
Yes 20 10 (50) 3.00 (1.10–8.21)
Haemodialysis 0.018
No 88 22 (25) 1 (ref)
Yes 16 9 (56) 3.86 (1.29–11.58)
Pitt score 2 0.004
No 37 5 (14) 1 (ref)
Yes 60 25 (42) 4.57 (1.56–13.70)
Missing 7
Time from
candidaemia to
antifungal therapy
(days)
2 (1–3) 2 (1–3) — 0.761
Type of antifungal
therapyf
0.220
Azolesg 28 12 (43) 1 (ref)
Lipid formulations of
AmB
11 3 (27) 0.50 (0.11–2.29)
Echinocandins 57 14 (25) 0.43 (0.17–1.14)
Missing 8
Concomitant
bacteraemia
0.317
No 77 25 (32) 1 (ref)
Yesh 27 6 (22) 0.59 (0.21–1.66)
Concomitant iv
antibiotics
0.697
No 17 6 (35) 1 (ref)
Yes 82 25 (30) 0.80 (0.27–2.42)
Missing 5
Initial BDG >287 pg/
mL
0.001
No 62 11 (18) 1 (ref)
Yes 42 20 (48) 4.22 (1.73–10.26)
Timing of BDG testi 0.937
 ±24 hours 43 13 (30) 1 (ref)
> ±24 hours 61 18 (30) 0.97 (0.41–2.27)
AmB, amphotericin B; ANC, absolute neutrophil count; BDG, (1,3)-β-D-glucan; CI,
conﬁdence interval; CVC, central venous catheter; HSCT, haematopoietic stem cell
transplantation; ICU, intensive care unit; IQR, interquartile range; OR, odds ratio;
ULN, upper limit of normal (set at 1.3 mg/dL).
aData are presented as median (interquartile range) or n (%).
bMissing refers to data not available in medical charts or databases.
cC. glabrata 7/55 (13%), C. krusei 8/55 (15%), C. kefyr 1/55 (2%), C. parapsilosis 23/55
(42%), C. lusitaniae 1/55 (2%), C. tropicalis 10/55 (18%), or polymicrobial 5/55 (9%).
dC. albicans + C. glabrata, C. lusitaniae + C. albicans, C. albicans + C. parapsilosis, C.
albicans + C. tropicalis, and C. glabrata + C. parapsilosis.
eEndocarditis, n = 3; endophthalmitis, n = 4.
fFluconazole, n = 26; voriconazole, n = 2; caspofungin, n = 41; anidulafungin, n = 12;
micafungin, n = 4; lipid formulations of AmB, n = 11.
gAfter at least 48 days of therapy, in 7/28 patients azoles were substituted with a
lipid formulation of AmB (n = 4) or micafungin (n = 3).
hAcinetobacter baumannii 2/27 (7%), Escherichia coli 3/27 (11%), Enterococcus spp. 8/27
(30%), Klebsiella pneumoniae 3/27 (11%), Enterobacter spp. 1/27 (4%), Staphylococcus
aureus 3/27 (11%), Proteus spp. 1/27 (4%), Morganella morganii 2/27 (7%), or poly-
microbial 4/27 (15%).
iWith respect to the positive blood culture for Candida spp.; ±24 h, 24 hours before
or after the positive blood culture.
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Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectPPV and NPV of initial BDG as a prognostic marker at different
cutoff values. The 287 pg/mL cutoff appeared to be the best
compromise between sensitivity and speciﬁcity in our popula-
tion (sensitivity 65%, speciﬁcity 70%, PPV 48%, NPV 82%).
Different balances between sensitivity, speciﬁcity and PPV could
be attained by moving the cutoff up or down, while no modi-
ﬁcation of the cutoffs signiﬁcantly changed the NPV. The area
under the ROC curve was 0.705 (Fig. 2).
The effects of modifying factors on the ability of initial BDG
to predict the 28-day mortality are reported in Fig. 3. A sta-
tistically signiﬁcant interaction was found between initial BDG
levels and the centre of enrolment (p 0.012). This indicated thatious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 954.e9–954.e17
FIG. 2. ROC curve for performance of initial BDG as predictor of
mortality for entire study population (104 patients). AUC, area under
curve; BDG (1,3)-β-D-glucan; ROC, receiver operating characteristic.
Prognostic performances for different cutoff levels are summarized in
Table 4.
TABLE 3. Multivariate analysis of risk factors for 28-day
mortality in patients with candidaemia
Variable OR (95% CI) pa
Initial BDG > 287 pg/mL 0.005
No 1 (ref)
Yes 4.40 (1.56–12.39)
Pitt score 2 0.021
No 1 (ref)
Yes 4.10 (1.24–13.54)
Haemodialysis 0.022
No 1 (ref)
Yes 4.33 (1.24–15.17)
Recent surgical procedures 0.106
No 1 (ref)
Yes 0.43 (0.15–1.20)
Gender — 0.310
Serum creatinine >2-fold ULN — 0.788
BDG, (1,3)-β-D-glucan; CI, conﬁdence interval; OR, odds ratio; ULN, upper limit of
normal (set at 1.3 mg/dL).
aVariables with p <0.15 in the univariate analysis were considered for the multi-
variate model, that included 97/104 patients (93%, missing = 7, due to unavailability
of Pitt score values for 7 patients).
CMI Giacobbe et al. Serum (1,3)-β-D-glucan as predictor of mortality 954.e14the association of the initial BDG value with mortality was
limited to the Italian cohort. In this regard, it is worth noting
that haemodialysis and timing of BDG test of more than 24
hours before or after the positive culture, which were both
signiﬁcantly more common in the Brazilian cohort than in the
Italian cohort (Table 1), also appeared to interfere with ability
of the BDG value to predict mortality, although the associations
were not statistically signiﬁcant (p value for interaction 0.062,
0.143, respectively).DiscussionIn the present study, as many as one third of the patients died
within 28 days after the development of candidaemia, which is
consistent with the high mortality rates reported in several
studies [1,2]. An initial BDG value of >287 pg/mL independentlyTABLE 4. Sensitivity, speciﬁcity, PPV and NPV of initial BDG as a
Cutoff (pg/mL)
No./total of patients:
Above cutoff (nonsurvivor) Below cutoff (survivor)
>40 27/31 24/73
>80 26/31 36/73
>120 25/31 39/73
>160 23/31 44/73
>200 21/31 48/73
>240 20/31 49/73
>280 20/31 51/73
>287 20/31 51/73
>320 20/31 51/73
>360 19/31 51/73
>400 19/31 52/73
>440 18/31 55/73
>480 17/31 55/73
>520 17/31 55/73
BDG, (1,3)-β-D-glucan; PPV, positive predictive value; NPV, negative predictive value.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infpredicted 28-day mortality in patients with proven candidaemia
when cases from two teaching hospitals in Italy and Brazil were
considered together, although this effect was present only in
the Italian cohort when the two cohorts were considered
separately.
Although the relationship between the levels of circulating
BDG and the severity of candidaemia is still to be fully under-
stood, we hypothesized that a high initial BDG level might
adversely affect survival, as it would reﬂect a higher fungal
burden. Indeed, increased serum values of fungal antigens have
already been proven to predict mortality in haematopoietic
stem cell transplant recipients with invasive aspergillosis, as highpredictor of mortality at different cutoff levels
Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
87 33 35.5 85.7
84 49 41.2 87.8
81 54 42.4 86.7
74 60 44.2 84.6
68 66 45.7 82.8
65 67 45.5 81.7
65 70 47.6 82.3
65 70 47.6 82.3
65 70 47.6 82.3
61 70 46.3 81.0
61 71 47.5 81.3
58 75 50.0 80.9
55 75 48.6 79.7
55 75 48.6 79.7
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FIG. 3. Odds ratio for 28-day mortality in patients with initial BDG >287 pg/mL with respect to patients with initial BDG 287 pg/mL in different
subgroups. Solid line shows no effect point, and dotted line shows overall effect on mortality of initial BDG >287 pg/mL for whole data set. All variables
were categorical. Beside subgroups according to variables included in ﬁnal multivariate model for mortality reported in Table 3 (i.e. previous surgical
procedures, haemodialysis and Pitt score 2), also the following subgroup analyses are presented: by presence of concomitant bacteraemia due to its
possible capability of inﬂuencing serum BDG levels, by centre of enrolment, by timing of BDG with respect to positive blood culture and by timing of
initiation of antifungals with respect to initial BDG measurement. All p values shown are two sided and are from tests for interaction, except for last at
bottom, which is p for comparison of patients with initial BDG >287 pg/mL vs. those patients with initial BDG 287 pg/mL in entire study population;
±24 h, 24 hours before or after the positive blood culture.
954.e15 Clinical Microbiology and Infection, Volume 21 Number 10, October 2015 CMIinitial serum galactomannan values were associated with
increased mortality in these patients [19,20]. However, as
regards BDG, the association between its initial serum levels
and mortality was controversial. Shimizu and colleagues [21]
reported an association between high BDG levels and mortal-
ity among 15 patients with connective tissue diseases who
developed Pneumocystis jiroveci pneumonia, while Watanabe
et al. [22] and Koga et al. [23] observed no signiﬁcant differ-
ences in initial BDG levels between survivors and nonsurvivors
in 17 and 111 AIDS patients with P. jiroveci pneumonia,
respectively. In the case of invasive candidiasis, a decrease in
BDG values during antifungal therapy has been reported to be a
potential marker of treatment success, but the prognostic role
of initial BDG values was not fully elucidated [11–13]. JaijakulClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectet al. [11] found that a baseline BDG value of <416 pg/mL
predicted treatment success with an 89% PPV in 203 patients
with invasive candidiasis enrolled onto an open-label trial and
treated with anidulafungin. In that study, response to treatment
was observed in 62% of patients with BDG <416 pg/mL versus
38% in BDG 416 pg/mL. On the contrary, a single-centre
observational study did not detect any signiﬁcant association
between initial BDG levels and treatment success among 67
subjects with invasive candidiasis [24]. It is worth noting that
both studies were not designed to evaluate the role of BDG as a
predictor of mortality.
In our study, a statistically signiﬁcant association was found
between initial BDG levels of >287 pg/mL and 28-day mortality
in patients with proven candidaemia. This cutoff value wasious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 954.e9–954.e17
CMI Giacobbe et al. Serum (1,3)-β-D-glucan as predictor of mortality 954.e16chosen before the analysis after having noted a bimodal distri-
bution of the initial BDG levels in the study population, and
therefore was not inﬂuenced by knowledge of patients’ out-
comes. It is worth noting that the shape of the distribution was
not altered by either the timing of the BDG sample with
respect to candidaemia or by considering the Italian and Bra-
zilian populations separately (Fig. 1). However, even though the
distributions of initial BDG levels were similar in the two
populations, with similar median values, the association be-
tween initial BDG levels of >287 pg/mL and mortality was only
evident in the Italian cohort. This ﬁnding might be partly
explained by the interfering effect of haemodialysis, which was
signiﬁcantly more common in the Brazilian centre. Indeed,
haemodialysis is a well-recognized additional predictor of
mortality in critically ill patients, being mostly reserved for
those subjects with severe renal failure [25,26]. In the presence
of such an organ impairment, we might guess that even an
initially reduced fungal burden might have inﬂuenced survival.
Consistent with this hypothesis, in our study, haemodialysis was
associated with increased mortality, and it also appeared to
interfere with the ability of the BDG value to predict the
outcome of candidaemia. In addition, patients in the Brazilian
cohort were more likely to have a timing of initial BDG more
than 24 hours before or after the positive culture, which also
appeared to somewhat reduce the predictive ability of the
prognostic marker. However, although clinically interesting,
both these interactions were not statistically signiﬁcant, sug-
gesting that other unexplored factors might perhaps be alter-
native explanations for the observed centre-related difference.
Aside from BDG levels, other well-recognized factors
responsible for changes in mortality of candidaemia were
included in the analysis. However, it should be pointed out that
this study was not designed to adequately investigate the role of
already known predictors of mortality, such as CVC removal
and type of antifungal therapy [27–29]. Therefore, no ﬁrm
conclusions can be drawn from this study about the impact of
these factors on mortality from candidaemia.
Several limitations of our study must be acknowledged. First,
results were possibly biased by the presence of missing data and
the potential underreporting related to the retrospective na-
ture of the study. Another important limitation is that initial
BDG levels and/or mortality might have been affected by fac-
tors not explored in our analysis, such as exposure to BDG-
containing sponges or gauzes, albumin administration, prior
antifungal treatment and the presence of bioﬁlms [18,30,31]. It
should also be acknowledged that we could not evaluate the
true value of BDG levels >523 pg/mL, a factor that might have
slightly changed the bimodal shape of the curve.
Finally, in our study, the prognostic ability of BDG was
considerably higher when the sample was measured closer to theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inftime of the positive blood culture, thus suggesting that BDGmight
be a reliable prognosticmarker ifmeasuredwithin a shortwindow
of time. However, although reduced, in our study the association
between BDG andmortality was still observable beyond 24 hours
before or after candidaemia, suggesting that this association might
extend somewhat beyond the exact time of fungaemia.
In conclusion, our data show an association between higher
BDG concentrations and mortality that was independent of
other prognostic factors. Further study is needed to better
understand the kinetics of BDG.Transparency DeclarationAll authors report no conﬂicts of interest relevant to this
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